Ruggeri M, Basile M, Armuzzi A, Cicchetti A. Activity-based costing and budget analysis of vedolizumab versus conventional treatments in ulcerative colitis and Crohn’s disease: Analisi Organizzativa e di Budget Dell’introduzione di Vedolizumab Vs Terapie Tradizionali in Colite Ulcerosa e Morbo di Crohn. Grhta [Internet]. 2017 Aug. 4 [cited 2024 Nov. 24];4(1):88-99. Available from: https://journals.aboutscience.eu/index.php/grhta/article/view/382